Anteris Technologies Global Corp. (AVR) · Sep 23, 2026 · Material agreement
4-month supply extension — Supply continued for four months after May 24, 2026
Anteris preserves a key supply relationship for DurAVR, yet the four-month extension mostly confirms an already disclosed contingency—not a new strategic win.
Anteris is still a development-stage structural-heart company building the DurAVR transcatheter heart valve toward commercialization, with manufacturing capacity being expanded to support the PARADIGM clinical program. The filing preserves continuity, not momentum: Harvey agreed to keep supplying Anteris for four additional months after the agreement’s initial term ended on May 24, 2026. 〔0〕 That avoids an immediate interruption to a supplier relationship tied to the company’s product-development and manufacturing effort, but it does not establish a durable long-term arrangement or add new economics.
Most of the news was already known: Anteris had previously disclosed that the Harvey agreement expired in May 2026 and that Harvey would continue supplying for four months if the agreement was not extended. The 8-K therefore formalizes the expected contingency almost at the end of that bridge period rather than changing the company’s commercial or clinical trajectory.
Bottom line: This is operationally useful but strategically routine: DurAVR’s supply line remains intact, while the filing leaves the longer-term supply question unresolved and adds little beyond prior disclosure. 〔1〕
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!